Send to

Choose Destination
See comment in PubMed Commons below
Pharmacogenet Genomics. 2013 Nov;23(11):627-30. doi: 10.1097/FPC.0b013e3283659a94.

CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment.

Author information

Departments of aGenetics and Genomics bPsychiatry, IIS - Fundacion Jimenez Diaz University Hospital cCIBERER ISCIII dDepartment of Biology, Autonomous University of Madrid, CBMSO, CSIC eDepartment of Clinical Pharmacology, La Princesa University Hospital, IIS Princesa fCIBEREHD ISCIII gDepartment of Preventive Medicine, Public Health and Medical Immunology and Microbiology, School of Health Sciences, Rey Juan Carlos University hCIBERSAM ISCIII, Madrid iCICAB, Clinical Research Centre, Extremadura University Hospital and Medical School, Badajoz, Spain jDepartment of Psychiatry, Columbia University, New York, New York, USA.


The variability in the antipsychotic response is, to some extent, genetically determined. Several studies have attempted to establish a role for genetic variation in genes coding pharmacokinetic and pharmacodynamic targets, but to date, no definite genetic predictive marker has been identified. We aimed to explore the putative role of 19 genetic variants and risperidone clinical improvement in 76 White schizophrenic inpatients, measured as change in Positive and Negative Syndrome Scale (PANSS). CYP2D6 poor metabolism was significantly associated with greater clinical improvement in total PANSS and a trend was also found for MDR1 3435C>T to higher total PANSS scores in 3435T carriers. This study suggests the importance that genetic variability on pharmacokinetic factors may have in risperidone response and gives evidence for the need for further investigation in order to establish the actual predictive value and clinical utility that CYP2D6 genotyping might have in risperidone therapy management.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins - Ovid Insights
    Loading ...
    Support Center